Back to search
FDAFDA · Food and drugs·Recall number D-0544-2022

Ephedrine 25 Guaifenesin 200 Tablet (Ephedrine HCl 25 mg, Guaifenesin 200 mg) Bulk Container, ULTRAtab Laboratories, Inc., Highland, NY NDC 62959-320-00

Published February 16, 2022 · Recall initiated: January 26, 2022

Summary

FDA records drug Class II recall D-0544-2022, published February 16, 2022 and initiated January 26, 2022. Recalling firm: ULTRAtab Laboratories, Inc.; Status: Terminated; Reported quantity: 7,297,709 tablets; Lot: Product Codes: M320L Bulk Lots: 18M063, 19G076. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ULTRAtab Laboratories, Inc.
Distributor
Bulk product was distributed to 3 distributors who may have distributed finished product.
Lot
Product Codes: M320L Bulk Lots: 18M063, 19G076
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ephedrine 25 Guaifenesin 200 Tablet (Ephedrine HCl 25 mg, Guaifenesin 200 mg) Bulk Container, ULTRAtab Laboratories, Inc., Highland, NY NDC 62959-320-00 recalled?

Yes. FDA published recall D-0544-2022 on February 16, 2022. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter